Kieran Le Plastrier: Quit moralising and embrace the potential of weight loss drugs
Yet that's precisely what we're seeing with GLP-1 receptor agonists — commonly known by brand names including Ozempic and Mounjaro.
Initially developed as a treatment for diabetes, these drugs are now proving to be nothing short of transformative for millions of people worldwide.
But while their potential is vast, our access to them remains frustratingly narrow.
There's a common misconception that these drugs are only a tool for weight loss and diabetes management.
But that's far from the limit of their potential.
These medications are showing promise in reducing the risk of heart disease, stroke, kidney failure, liver disease, and even dementia.
They're also being explored as tools to combat addiction — blunting the brain's reward system and helping people overcome dependencies on alcohol, nicotine, and other substances.
We are standing at the edge of a paradigm shift in how we treat chronic disease.
Yet in Australia, access to these drugs is largely restricted to people with uncontrolled diabetes at a subsidised cost under the Pharmaceutical Benefits Scheme.
While they can be prescribed off-label for other conditions, such as obesity, without the PBS subsidy the cost can be anything from $55 to $130 a dose, which most people simply can't afford.
Obesity is not a personal moral failing. It is a complex, multi-factorial condition driven by genetics, environment, and a society that promotes sedentary lifestyles and calorie-dense foods.
We live in an obesogenic world, and blaming individuals for their biology is both unjust and ineffective.
The UK's NHS has already recognised this, moving to subsidise GLP-1 drugs for people with obesity to reduce long-term disease burden.
Australia must follow suit. The cost of inaction — measured in heart attacks, strokes, hospital admissions, and lives lost — is far greater than the cost of these medications.
Now, these drugs are not a silver bullet. They work best as part of a holistic approach that includes dietary support, physical activity, and psychological care.
And as for every powerful therapeutic drug, risks exist and must be carefully considered and managed under the care of expert health practitioner
But they offer something we've never had before: a safer, effective, and scalable way to intervene in the metabolic cascade that underpins so many of our modern diseases.
We need to stop treating these drugs as luxury items for the wealthy or as quick fixes for vanity.
They are powerful tools for prevention and healing.
It's time our health system caught up with the science.
Dr Kieran Le Plastrier is a GP and Assistant Professor of General Practice at Bond University
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
ABC News
40 minutes ago
- ABC News
Novo Nordisk names new CEO amid share price slump and concerns over Wegovy, Ozempic sales
Danish pharmaceutical giant Novo Nordisk, known for its weight-loss drugs Wegovy and Ozempic, has named Maziar Mike Doustdar as its new chief executive, relying on an experienced company insider to make up ground lost to market rivals. Mr Doustdar's appointment came on Tuesday after the abrupt removal in May of his predecessor Lars Fruergaard Jorgensen by Novo and the Novo Nordisk Foundation — the company's controlling shareholder. The new CEO joined Novo in 1992 and currently serves as vice-president for international operations, a role he took after leading the company's businesses first in the Middle East and then in South-East Asia, Novo said. His most urgent challenge, according to investors and analysts, is to revive Novo's performance in the United States, the largest market by far for weight-loss drugs and where they are most profitable. Novo launched its weight-loss drug Wegovy nearly two-and-a-half years before its US rival Eli Lilly's Zepbound. Zepbound prescriptions surpassed those of Wegovy this year by more than 100,000 a week. The appointment comes at a challenging time for the global pharmaceutical industry as US President Donald Trump threatens to impose tariffs on imports and calls on drug makers to lower their American prescription prices. Mr Jorgensen led Novo through a period of meteoric growth as it led the weight-loss drug boom, becoming Europe's most valuable listed company after the launch of Wegovy in 2021. At its peak in June 2024 Novo was worth as much as $US615 billion ($946.4b). Novo shares have plunged over the past 12 months, amid investor concerns about the company's experimental drug pipeline and its ability to navigate challenges in the US market, such as the threat to its sales from compounded copies of Wegovy and Lilly's Zepbound. On Tuesday, Novo cut its full-year sales and operating profit forecasts for the second time this year, sending its shares down as much as 17 per cent. "The lowered sales outlook for 2025 is driven by lower growth expectations for the second half of 2025," the company said in a statement. "This is related to lower growth expectations for Wegovy in the US obesity market, lower growth expectations for Ozempic in the US GLP-1 diabetes market, as well as lower-than-expected penetration for Wegovy in select IO (International Operations) markets." Novo now expects 2025 sales growth of between eight and 14 per cent in local currencies, down from its previous forecast range of between 13 and 21 per cent. It also lowered its operating profit growth estimate to between 10 and 16 per cent, down from 16 to 24 per cent previously. Sales rose 18 per cent year-on-year in both the second quarter and the first half of the year, Novo said. Its operating profit increased by 40 per cent in the April-June quarter and by 29 per cent in the first half, the company added. Booming sales of Wegovy catapulted Novo to become Europe's most valuable listed company in 2024, peaking at about 615 billion euros ($1.09t), but the value has since fallen by more than half. The company is scheduled to release full second-quarter earnings on August 6. Reuters
The Advertiser
3 hours ago
- The Advertiser
A smile, though endometriosis is no laughing matter
Cara Walker was all smiles when she met Anthony Albanese, but as a woman living with endometriosis, she knows the strain that comes with managing a chronic condition. Labor is preparing to introduce legislation to parliament this week which will cap the cost of prescriptions on the Pharmaceutical Benefits Scheme to $25 from $31.60 from 2026. Ahead of the bill being presented to the lower house, the prime minister and Health Minister Mark Butler on Tuesday hosted a group of women impacted by endometriosis to discuss the changes. Endometriosis is a disease which tissue grows outside of the uterus, often causing severe pain. Labor amended and made new listings for contraception, endometriosis and IVF on the PBS ahead of the federal election campaign this year. Ms Walker told Mr Albanese chopping and changing between medications to manage chronic conditions quickly added up and was a hit to the hip pocket. "For people who don't have chronic conditions, all of a sudden they could get a cancer diagnosis, something could happen, and that puts a lot of strain on families, so that helps ease that strain, and every little bit counts," she said. Labor made health a centrepiece of its election campaign, pledging $8.5 billion to strengthen Medicare in a bid to make nine out of 10 visits to the GP free by 2030. Pressed during Question Time about bulk billing rates, Mr Albanese pulled out a Medicare card, as he had often done on the campaign trail. "The timeline hasn't changed, the investment is unchanged, the modelling is the same," the prime minister said. Mr Butler also clarified the figures around expected uptake of an expanded bulk billing incentive following criticism rates would take years to improve. But the health minister defended the government's modelling which expects fully bulk-billed practices to rise from about a quarter to three. Opposition health spokeswoman Anne Ruston said people going to the doctor were paying out of pocket costs higher than what they had ever been. "Right the way through the election campaign, the prime minister waving around his Medicare card and telling Australians and I quote, 'All you'll need is your Medicare card, not your credit card,' was actually misleading the Australian public about the reality that is currently our health care system at the moment," she told ABC's RN. Cara Walker was all smiles when she met Anthony Albanese, but as a woman living with endometriosis, she knows the strain that comes with managing a chronic condition. Labor is preparing to introduce legislation to parliament this week which will cap the cost of prescriptions on the Pharmaceutical Benefits Scheme to $25 from $31.60 from 2026. Ahead of the bill being presented to the lower house, the prime minister and Health Minister Mark Butler on Tuesday hosted a group of women impacted by endometriosis to discuss the changes. Endometriosis is a disease which tissue grows outside of the uterus, often causing severe pain. Labor amended and made new listings for contraception, endometriosis and IVF on the PBS ahead of the federal election campaign this year. Ms Walker told Mr Albanese chopping and changing between medications to manage chronic conditions quickly added up and was a hit to the hip pocket. "For people who don't have chronic conditions, all of a sudden they could get a cancer diagnosis, something could happen, and that puts a lot of strain on families, so that helps ease that strain, and every little bit counts," she said. Labor made health a centrepiece of its election campaign, pledging $8.5 billion to strengthen Medicare in a bid to make nine out of 10 visits to the GP free by 2030. Pressed during Question Time about bulk billing rates, Mr Albanese pulled out a Medicare card, as he had often done on the campaign trail. "The timeline hasn't changed, the investment is unchanged, the modelling is the same," the prime minister said. Mr Butler also clarified the figures around expected uptake of an expanded bulk billing incentive following criticism rates would take years to improve. But the health minister defended the government's modelling which expects fully bulk-billed practices to rise from about a quarter to three. Opposition health spokeswoman Anne Ruston said people going to the doctor were paying out of pocket costs higher than what they had ever been. "Right the way through the election campaign, the prime minister waving around his Medicare card and telling Australians and I quote, 'All you'll need is your Medicare card, not your credit card,' was actually misleading the Australian public about the reality that is currently our health care system at the moment," she told ABC's RN. Cara Walker was all smiles when she met Anthony Albanese, but as a woman living with endometriosis, she knows the strain that comes with managing a chronic condition. Labor is preparing to introduce legislation to parliament this week which will cap the cost of prescriptions on the Pharmaceutical Benefits Scheme to $25 from $31.60 from 2026. Ahead of the bill being presented to the lower house, the prime minister and Health Minister Mark Butler on Tuesday hosted a group of women impacted by endometriosis to discuss the changes. Endometriosis is a disease which tissue grows outside of the uterus, often causing severe pain. Labor amended and made new listings for contraception, endometriosis and IVF on the PBS ahead of the federal election campaign this year. Ms Walker told Mr Albanese chopping and changing between medications to manage chronic conditions quickly added up and was a hit to the hip pocket. "For people who don't have chronic conditions, all of a sudden they could get a cancer diagnosis, something could happen, and that puts a lot of strain on families, so that helps ease that strain, and every little bit counts," she said. Labor made health a centrepiece of its election campaign, pledging $8.5 billion to strengthen Medicare in a bid to make nine out of 10 visits to the GP free by 2030. Pressed during Question Time about bulk billing rates, Mr Albanese pulled out a Medicare card, as he had often done on the campaign trail. "The timeline hasn't changed, the investment is unchanged, the modelling is the same," the prime minister said. Mr Butler also clarified the figures around expected uptake of an expanded bulk billing incentive following criticism rates would take years to improve. But the health minister defended the government's modelling which expects fully bulk-billed practices to rise from about a quarter to three. Opposition health spokeswoman Anne Ruston said people going to the doctor were paying out of pocket costs higher than what they had ever been. "Right the way through the election campaign, the prime minister waving around his Medicare card and telling Australians and I quote, 'All you'll need is your Medicare card, not your credit card,' was actually misleading the Australian public about the reality that is currently our health care system at the moment," she told ABC's RN. Cara Walker was all smiles when she met Anthony Albanese, but as a woman living with endometriosis, she knows the strain that comes with managing a chronic condition. Labor is preparing to introduce legislation to parliament this week which will cap the cost of prescriptions on the Pharmaceutical Benefits Scheme to $25 from $31.60 from 2026. Ahead of the bill being presented to the lower house, the prime minister and Health Minister Mark Butler on Tuesday hosted a group of women impacted by endometriosis to discuss the changes. Endometriosis is a disease which tissue grows outside of the uterus, often causing severe pain. Labor amended and made new listings for contraception, endometriosis and IVF on the PBS ahead of the federal election campaign this year. Ms Walker told Mr Albanese chopping and changing between medications to manage chronic conditions quickly added up and was a hit to the hip pocket. "For people who don't have chronic conditions, all of a sudden they could get a cancer diagnosis, something could happen, and that puts a lot of strain on families, so that helps ease that strain, and every little bit counts," she said. Labor made health a centrepiece of its election campaign, pledging $8.5 billion to strengthen Medicare in a bid to make nine out of 10 visits to the GP free by 2030. Pressed during Question Time about bulk billing rates, Mr Albanese pulled out a Medicare card, as he had often done on the campaign trail. "The timeline hasn't changed, the investment is unchanged, the modelling is the same," the prime minister said. Mr Butler also clarified the figures around expected uptake of an expanded bulk billing incentive following criticism rates would take years to improve. But the health minister defended the government's modelling which expects fully bulk-billed practices to rise from about a quarter to three. Opposition health spokeswoman Anne Ruston said people going to the doctor were paying out of pocket costs higher than what they had ever been. "Right the way through the election campaign, the prime minister waving around his Medicare card and telling Australians and I quote, 'All you'll need is your Medicare card, not your credit card,' was actually misleading the Australian public about the reality that is currently our health care system at the moment," she told ABC's RN.
Sydney Morning Herald
5 hours ago
- Sydney Morning Herald
CD96: How Mark Smyth hoped to build a cancer-buster
CD96 is a receptor protein on the surface of two types of immune cells: natural killer cells and killer T cells. They are responsible for continuously screening our bodies for foreign invaders. Killer T cells typically reside in our lymph nodes (in the neck and armpits; they swell when we get sick) and spleen. Our lymphatic system can be seen as our body's sewer piping – if there's a foreign invader, it will show up here sooner or later. T cells have a main receptor that can sense foreign nasties, plus lots of secondary receptors. When the main receptors get a hit, they massively multiply and leave the sewers to attack the invader. 'Everything is about shape with this,' said one immunologist, speaking anonymously to discuss the Smyth matter. 'Each of your T cell receptors, you've just got this massive amount of diversity on what they look like. So you are prepared to recognise anything you might come across in your life.' The main receptor does the bulk of the work. The secondary receptors can also sense and bind to the foreign adversary; their job is to fine-tune the immune response. Now we add a key wrinkle: immune cells also need to be able to recognise normal human cells – otherwise we would be destroyed from the inside out. They do this with the secondary receptors, which look for certain proteins on our cells that mark them as friend, not foe. One last idea, before we get to CD96. Our immune system is quite effective at hunting and killing cells that become cancerous. But occasionally, a cancerous cell acquires a collection of genetic mutations that cause it to throw up a protein that mimics the ones on a healthy cell. So our immune cells leave them alone, and they grow and grow into thick tumours. A drug to melt cancer In the early 2000s, a small group of scientists, Smyth among them, argued it might be possible to use genetically engineered antibodies to gum up some of the receptors on immune cells – unleashing their destructive power on cancers. Many scientists were initially sceptical that such a technique could ever work. Smyth was an early believer, and he was right. Checkpoint inhibitors – drugs that unleash the immune system to attack cancer – are one of the great triumphs of 21st-century science. In 2018, James Allison and Tasuku Honjo were awarded the Nobel Prize for showing how the gumming up of two receptors, CTLA-4 and PD-1, revealed cancer to the immune system. Smyth dreamt CD96, his lab's focus, might one day stand alongside the work on CTLA-4 and PD-1 as powerful cancer-busting weapons. CD96 can bind to a protein called CD155. It shares this ability with two other receptors, TIGIT and CD226. Scientists first came across it in 2004 as a natural killer cell activator – it seemed to trigger natural killer cell attack. CD226 seemed to do the same thing, while TIGIT seemed to turn off the attack. To build a checkpoint inhibitor drug, you need to find and block a receptor that inhibits T cell attack – remember, we're trying to take the brakes off the immune system. An activator like CD96 is not very useful for this purpose. Then in 2014, a team including Mark Smyth published a highly influential paper in Nature Immunology. CD96 wasn't just an activator, they said. It was a competitor with CD226. Removing CD96 in mice seemed to allow more CD226 to bind – allowing the immune system to spot and attack cancer. Scientists often bury the most important lines in a paper right at the end. Here's the one from the 2014 paper co-authored by Smyth. 'Inhibition of checkpoint molecules on lymphocytes (T cells and NK cells) is proving a useful approach for the treatment of human cancers. Blocking the interaction of CD96 with CD155 may open new opportunities for increasing the recognition of tumor cells.' Smyth's team was essentially saying that it might be possible to block CD96 and create a new immune checkpoint drug. British pharma company GSK took notice. The company filed a patent in 2020 for an antibody that binds to CD96. 'The first paper indicating CD96 as a potential immuno oncology target was published by the lab of Professor Mark Smyth in 2014,' the patent reads. GSK launched a phase 1 human clinical trial of the drug, known as Nelistotug, in 2020. Results are expected later this year. Does the drug work? We don't know, as we don't have the results. The 2014 paper on CD96 has not been retracted, and GSK did a range of its own tests on CD96 that it stands behind. 'Our robust oncology research and development program, including our investigations of Nelistotug in combination with other therapies, is always based on the full breadth of scientific evidence available,' a GSK spokeswoman said. * Name has been changed to protect the source.
